Semaglutide/l-carnitine is a compounded GLP-1 injectable that pairs semaglutide with the amino acid L-carnitine. Learn how it works, side effects, and safety.
Semaglutide/l-carnitine is a compounded injectable that pairs semaglutide, the GLP-1 medication inside Ozempic and Wegovy, with L-carnitine, an amino acid derivative involved in fat metabolism. It is not an FDA-approved drug product, and the FDA declared the semaglutide shortage resolved in early 2025, which sharply limited how compounding pharmacies can make copies. Anyone considering it should treat it as an unapproved formulation and review it with a licensed healthcare professional before injecting anything.
What Is Semaglutide/L-Carnitine?
Semaglutide is a GLP-1 receptor agonist. It mimics a gut hormone that slows stomach emptying, signals fullness to the brain, and improves blood sugar control. The FDA has approved semaglutide as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management.
L-carnitine is a compound the body builds from the amino acids lysine and methionine and also absorbs from red meat and dairy. Its main job is to shuttle long-chain fatty acids into mitochondria, where cells burn them for energy.
In compounded versions, a pharmacy mixed both ingredients into a single vial, usually for once-weekly injection. Patients often describe the product as semaglutide l carnitine, and doses are frequently measured in units on a syringe rather than milligrams, because concentrations differ from one pharmacy to the next.
Why Compounding Pharmacies Added L-Carnitine
There is no FDA-reviewed scientific rationale for the pairing. The practical reasons were mostly commercial and logistical.
- Marketing: Labeling that mentions "fat burning" makes a compounded vial sound more powerful than plain semaglutide, even without data to back it up.
- Perceived tolerability: Some prescribers believed L-carnitine might soften nausea or injection-site discomfort. That idea has never been tested in a controlled trial.
- Differentiation: During the semaglutide shortage, pharmacies competed for the same limited API supply, and a distinctive formulation helped a pharmacy stand out.
None of those reasons involved FDA review of the finished combination, its potency, or its sterility.
Semaglutide With L-Carnitine Benefits: What Research Supports
Semaglutide's benefits are well documented. L-carnitine's contribution alongside it is mostly theoretical. The idea of semaglutide with l-carnitine benefits usually comes from marketing language rather than from head-to-head trials.
| Claim | What the evidence actually shows |
|---|---|
| Extra weight loss beyond semaglutide alone | No controlled trial shows an added effect from L-carnitine |
| Faster fat burning | L-carnitine does transport fatty acids, but supplement trials show inconsistent fat loss in humans |
| Less nausea | Anecdotal reports only; no controlled data |
| More energy or better exercise performance | Mixed results in small athletic studies |
| Fewer injection-site reactions | Not studied |
In the STEP 1 trial, weekly semaglutide 2.4 mg produced roughly 14.9% average body weight loss over 68 weeks. That result came from semaglutide, not from any added amino acid.
Most documented l-carnitine benefits come from people who are genuinely deficient, such as dialysis patients, where supplementation corrects a shortage the body cannot fix on its own. Weight loss in people without a deficiency is not an established use.
Semaglutide L-Carnitine Side Effects
Most reported reactions trace back to semaglutide, because GLP-1 medications act on the gut and the brain. Common effects include nausea, vomiting, diarrhea, constipation, abdominal pain, heartburn, burping, and fatigue, usually worst during dose increases.
Rare but serious risks include pancreatitis, gallbladder disease, bowel obstruction, kidney injury from dehydration, and low blood sugar when semaglutide is combined with insulin or sulfonylureas. Semaglutide also carries a boxed warning about thyroid C-cell tumors seen in rodents and is contraindicated for people with a personal or family history of medullary thyroid carcinoma or MEN2.
L-carnitine itself is generally well tolerated, though high doses can cause stomach cramps, diarrhea, a fishy body odor, and a theoretical rise in TMAO, a compound some researchers link to cardiovascular risk.
Some users report feeling warm or flushed after injecting, and a common search is does l'carnitine cause excessive sweating. There is no consistent clinical evidence that L-carnitine triggers excessive sweating, so those reports are more likely tied to nausea, low blood sugar, or unrelated causes.
Anyone tracking semaglutide l-carnitine side effects should know that reporting is far less structured than for FDA-approved products, since compounded drugs skip the same review and post-market surveillance.
Semaglutide/L-Carnitine vs. FDA-Approved Semaglutide
| Feature | Compounded semaglutide/l-carnitine | Wegovy or Ozempic |
|---|---|---|
| FDA approval | Not approved as a combination product | Approved for specific uses |
| Active ingredients | Semaglutide plus L-carnitine | Semaglutide only |
| Dosing | Often measured in units; varies by pharmacy | Standardized, single-use pens |
| Cost | Often cheaper out of pocket | Higher list price; insurance may cover |
| Oversight | State pharmacy boards; limited FDA review | Full FDA review and labeling |
Other Combinations People Research
Semaglutide is not the only molecule discussed in weight-loss forums. AOD-9604 is a modified fragment of human growth hormone studied for fat metabolism, but it is not FDA-approved for weight loss and is not sold as a US prescription drug. Cagrilintide, an amylin analog, has been tested alongside semaglutide in late-stage trials under the name CagriSema, with reported weight loss in the low 20% range, but that product is not FDA-approved as of this writing. Dose schedules for research combinations belong to trial protocols and approved labels, not to internet summaries.
Safety, Legal Status, and Questions to Ask
In February 2025, the FDA declared the semaglutide shortage resolved. That decision meant state-licensed compounding pharmacies generally had to stop making copies of a commercially available drug, with limited exceptions, and enforcement has continued since.
If you are offered any compounded GLP-1, ask direct questions:
- Is the pharmacy licensed in my state, and is it a 503A or 503B facility?
- Has this specific lot been tested for potency and sterility?
- What is the exact concentration, and how do I measure one dose accurately?
- What is the plan if I develop severe nausea, vomiting, or abdominal pain?
- Is there an FDA-approved alternative my insurance will cover?
Bottom Line
Semaglutide/l-carnitine is not an FDA-approved drug combination, and it was created by compounding pharmacies rather than through clinical development.
Adding L-carnitine to semaglutide has no proven weight-loss benefit in controlled human trials.
Semaglutide is the ingredient with strong evidence for appetite reduction, weight loss, and blood sugar control, and it works on its own.
Compounded injectables vary in strength and quality, so use them only under medical supervision and only after discussing risks, alternatives, and monitoring with a healthcare professional.
Frequently Asked Questions
Is semaglutide/l-carnitine the same as Wegovy or Ozempic?
No. Wegovy and Ozempic contain semaglutide only and are FDA-approved for specific uses. Semaglutide/l-carnitine was a compounded combination that was never reviewed or approved by the FDA, and compounded copies became largely unavailable after the agency declared the semaglutide shortage resolved in early 2025.
Does the L-carnitine in the injection help you lose more weight?
There is no controlled evidence that L-carnitine adds weight loss on top of semaglutide. The weight loss seen in major trials, about 15% of body weight on average over 68 weeks, came from semaglutide alone. L-carnitine supplementation is best supported for correcting a deficiency, not for weight loss.
Can I still get compounded semaglutide with L-carnitine in the United States?
Availability tightened significantly after the FDA resolved the semaglutide shortage in February 2025, because pharmacies generally cannot make copies of a drug that is commercially available. Limited exceptions and ongoing litigation mean the situation can change, so check with a licensed pharmacist and your prescriber about what is currently permitted in your state.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.